SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| PLENDIL 10MG S.R.TAB | 10 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 42.85 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| PLENDIL 5MG S.R. TAB | 5 mg | Prolonged-release tablet · Oral use | 30 Blister | SAR 23.80 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | GLENMARK PHARMS LTD | Prescription | 17 Dec 2010 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | PH HEALTH | Prescription | 28 Oct 2011 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | TORRENT PHARMS LTD | Prescription | 28 Nov 2011 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | AUROBINDO PHARMA LTD | Prescription | 17 Jan 2013 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | HERITAGE | Prescription | 8 Nov 2013 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | SUN PHARM INDS LTD | Prescription | 13 Dec 2013 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | ORBION PHARMS | Prescription | 21 May 2015 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | YILING | Prescription | 26 Oct 2018 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | YUNG SHIN PHARM | Prescription | 29 Apr 2019 |
| PLENDIL | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, extended release · oral | ASTRAZENECA | Discontinued | 25 Jul 1991 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | SUN PHARM INDUSTRIES | Discontinued | 2 Nov 2004 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | MYLAN | Discontinued | 17 Apr 2008 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | WOCKHARDT BIO AG | Discontinued | 15 Aug 2012 |
| FELODIPINE | 2.5MG; 5MG; 10MG | tablet, extended release · oral | JUBILANT GENERICS | Discontinued | 19 Aug 2016 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| APO-FELODIPINE | 02452367 | 2.5 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-FELODIPINE | 02452375 | 5 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-FELODIPINE | 02452383 | 10 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| PLENDIL | 00851779 | 5 MG | TABLET (EXTENDED-RELEASE) · ORAL | GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE |
| PLENDIL | 00851787 | 10 MG | TABLET (EXTENDED-RELEASE) · ORAL | GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE |
| PLENDIL | 02057778 | 2.5 MG | TABLET (EXTENDED-RELEASE) · ORAL | GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE |
| SANDOZ FELODIPINE | 02280264 | 5 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ FELODIPINE | 02280272 | 10 MG | TABLET (EXTENDED-RELEASE) · ORAL | SANDOZ CANADA INCORPORATED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | FELODIPINE ER 10 MG TABLET | $0.13524 | per EA | 23 Sep 2026 |
| US NADAC | FELODIPINE ER 2.5 MG TABLET | $0.12686 | per EA | 23 Sep 2026 |
| US NADAC | FELODIPINE ER 5 MG TABLET | $0.12262 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Felodipine 10mg modified-release tablets | £3.61 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Felodipine 2.5mg modified-release tablets | £4.26 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Felodipine 5mg modified-release tablets | £2.90 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.